2021
Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchMeSH KeywordsFemaleHIV InfectionsHumansKyrgyzstanMaleMethadoneOpioid-Related DisordersPrisonersPrisonsRetrospective StudiesSubstance Abuse, IntravenousConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationRelease
2018
Retention in HIV care during the 3 years following release from incarceration: A cohort study
Loeliger KB, Meyer JP, Desai MM, Ciarleglio MM, Gallagher C, Altice FL. Retention in HIV care during the 3 years following release from incarceration: A cohort study. PLOS Medicine 2018, 15: e1002667. PMID: 30300351, PMCID: PMC6177126, DOI: 10.1371/journal.pmed.1002667.Peer-Reviewed Original ResearchConceptsViral suppressionInjection drug useHIV careCohort studyTreatment outcomesDrug useNational HIV prevention strategyMultivariable logistic regression modelCase management visitsProportion of followRetrospective cohort studyEarly linkageHIV prevention strategiesLongitudinal treatment outcomesHealth insuranceBetter treatment outcomesSubstance use disordersCase management servicesLogistic regression modelsAntiretroviral therapyCohort participantsManagement visitsCriminal justice populationsLarge cohortPsychiatric disordersAll-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007–14: a retrospective observational cohort study
Loeliger KB, Altice FL, Ciarleglio MM, Rich KM, Chandra DK, Gallagher C, Desai MM, Meyer JP. All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007–14: a retrospective observational cohort study. The Lancet HIV 2018, 5: e617-e628. PMID: 30197101, PMCID: PMC6279524, DOI: 10.1016/s2352-3018(18)30175-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultCause of DeathConnecticutFemaleHIV InfectionsHumansMaleMiddle AgedPrisonersPrisonsProportional Hazards ModelsRetrospective StudiesRisk FactorsConceptsIndex releaseCause mortalityMortality rateRetrospective observational cohort studyCox proportional hazards modelLow CD4 countObservational cohort studyHIV surveillance dataCrude mortality rateGeneral US populationProportional hazards modelStandardised mortality ratiosSubstance use disordersSystems of careHIV/AIDSSurvival of peopleVirological failureAntiretroviral therapyCD4 countMedical comorbiditiesCohort studyRetrospective cohortMedian ageLiver diseaseViral load
2017
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study
Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. The Lancet HIV 2017, 5: e96-e106. PMID: 29191440, PMCID: PMC5807129, DOI: 10.1016/s2352-3018(17)30209-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesHIV careViral suppressionTreatment outcomesPoor HIV treatment outcomesMore medical comorbiditiesPost-release linkagePredictors of linkageRetrospective cohort studyDetectable viral loadCase management servicesCase management dataTransitional case managementHealth care goalsAntiretroviral therapyMedical comorbiditiesCohort studyRetrospective cohortDays of releaseViral loadPharmacy databasePsychiatric comorbidityUS National InstitutesCase management needsHispanic ethnicityRetention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatment
2016
Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia.
Atkins KE, Pandey A, Wenzel NS, Skrip L, Yamin D, Nyenswah TG, Fallah M, Bawo L, Medlock J, Altice FL, Townsend J, Ndeffo-Mbah ML, Galvani AP. Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia. American Journal Of Tropical Medicine And Hygiene 2016, 94: 833-9. PMID: 26928839, PMCID: PMC4824226, DOI: 10.4269/ajtmh.15-0328.Peer-Reviewed Original ResearchMeSH KeywordsCommunity-Acquired InfectionsCross InfectionDisease OutbreaksHemorrhagic Fever, EbolaHumansLiberiaModels, StatisticalRetrospective StudiesConceptsCommunity transmissionEbola epidemicHospital transmissionAsymptomatic infectionImmune individualsRetrospective analysisEpidemiological dataUnreported casesDisease controlEbola dynamicsHospital capacityEpidemic patternsEbola incidenceFuture outbreaksPresence of interventionsEpidemicLiberian countiesTransmission reductionInfectionDiseaseIncidence
2015
Sex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates.
Meyer JP, Cepeda J, Taxman FS, Altice FL. Sex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates. American Journal Of Public Health 2015, 105: 1901-10. PMID: 26180958, PMCID: PMC4529767, DOI: 10.2105/ajph.2015.302687.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral suppressionSex-related differencesHigh prevalenceRisk scoreHIV treatment outcomesRetrospective cohort studyHIV viral suppressionLarge contemporary cohortSex-related disparitiesSex-specific interventionsCommunity-based treatmentWomen's higher prevalenceLogistic regression modelsCJ populationsTreatable comorbiditiesCohort studyHIV outcomesContemporary cohortTreatment outcomesHIVCJ involvementIncarceration durationOlder ageSignificant correlatesCost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLOS ONE 2015, 10: e0116694. PMID: 25658949, PMCID: PMC4320073, DOI: 10.1371/journal.pone.0116694.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCosts and Cost AnalysisFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPrevalenceRetrospective StudiesSubstance-Related DisordersUnited StatesConceptsQuality-adjusted life yearsOpioid substitution therapyHIV infectionHIV incidenceHIV prevalenceEvidence-based risk reduction interventionDynamic HIV transmission modelHolistic Health Recovery ProgramBehavioral HIV prevention interventionsFuture HIV incidenceTotal medical costsHIV transmission modelHIV prevention interventionsGeneral adult populationRisk reduction interventionsCost-effectiveness analysisSubstitution therapySexual transmissionHIV programsPrevention interventionsMedical costsTreatment settingsLife yearsReduction interventionsUS population
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimensSelf-Management of Buprenorphine/Naloxone Among Online Discussion Board Users
Brown SE, Altice FL. Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users. Substance Use & Misuse 2014, 49: 1017-1024. PMID: 24779501, PMCID: PMC5592159, DOI: 10.3109/10826084.2014.888449.Peer-Reviewed Original Research
2013
Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes
Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug And Alcohol Dependence 2013, 131: 127-135. PMID: 23332439, PMCID: PMC3674170, DOI: 10.1016/j.drugalcdep.2012.12.008.Peer-Reviewed Original ResearchConceptsQualified health centersSubstance abuse counselingHealth centersBuprenorphine maintenance treatment programCocaine useBuprenorphine maintenance therapyConcomitant cocaine useOpioid-dependent patientsMaintenance treatment programReal-world effectivenessSubstance abuse treatment outcomesElectronic health recordsHCV infectionMaintenance therapyPsychiatric comorbidityMean ageDependent patientsPsychiatric medicationsClinical trialsTreatment outcomesMood disordersFamily practitionersMore weeksTreatment programBMT
2012
Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortality
2008
Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations
Maru DS, Bruce RD, Basu S, Altice FL. Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases 2008, 47: 952-961. PMID: 18715156, PMCID: PMC4847716, DOI: 10.1086/591707.Peer-Reviewed Original ResearchConceptsSustained virological responseRate of prescriptionVirological responsePEG-RBVBaseline HCV RNA levelHepatic C virus infectionHCV genotype 1 infectionBaseline major depressionC virus infectionChronic HCV infectionHCV RNA levelsTreatment-naive patientsGenotype 1 infectionHepatitis C treatmentOutcome of treatmentUse of medicationsNewer mood stabilizersHCV infectionHIV infectionClinical outcomesMood stabilizersAntipsychotic medicationBlack raceClinical effectivenessMajor depression
2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchMeSH KeywordsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesHIV InfectionsHIV-1HumansPrisonersPrisonsRetrospective StudiesViral LoadConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount
2002
Effectiveness of a Mobile Medical Van in Providing Screening Services for STDs and HIV
Liebman J, Lamberti M, Altice F. Effectiveness of a Mobile Medical Van in Providing Screening Services for STDs and HIV. Public Health Nursing 2002, 19: 345-353. PMID: 12182694, DOI: 10.1046/j.1525-1446.2002.19504.x.Peer-Reviewed Original ResearchConceptsHigh-risk individualsMobile medical vanRisk individualsHIV control effortsConsistent condom useHigh-risk sexHIV testRetrospective studyAsymptomatic individualsScreening servicesSTD casesInvasive techniquesPositive casesDrug useCondom useNew casesActive casesHIVSTDsSmall proportionMedical programStudy communitiesIndividualsUrban settingsPatients
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatients